STOCK MARKET BSE NSE

Expert panel seeks additional data from Dr Reddy's laboratories on Russian COVID vaccine Sputnik V

In September last year, Dr Reddy's partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.

Published: 02nd April 2021 12:51 AM  |   Last Updated: 02nd April 2021 12:51 AM   |  A+A-

Russia's Sputnik V coronavirus vaccine arrives at Kosice Airport, Slovakia.

Russia's Sputnik V coronavirus vaccine (Photo | AP)

By PTI

NEW DELHI: An expert panel of India's central drug authority has sought additional data and information from Dr Reddy's Laboratories, which has sought emergency use authorisation for Russian COVID-19 vaccine Sputnik V, while deferring its decision on it till the next meeting, sources said.

In light of a February 24 meeting of the Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO), the firm presented the interim safety and immunogenicity data of the Gam-COVID-Vac combined vector vaccine generated in the country, along with the interim data from the ongoing Russian study.

According to the sources, the SEC, which deliberated on the EUA application on Thursday, recommended that the firm should present data pertaining to all immunogenicity parameters, unblinded data of serious adverse events and RT-PCR positive cases, along with causality analysis reported till date for further examination.

"It has also asked the Hyderabad-based firm to submit a comparative analysis of the phase 3 immunogenicity data generated on the Indian and Russian studies at various time points.

It has also asked the drug-maker to submit the factsheet," a source said.

"We have had our meeting with the SEC today and will await the feedback from the CDSCO. We will provide an update once we have the feedback," Dr Reddy's Laboratories said in a statement.

On February 19, the firm said it had approached drugs regulator DCGI for emergency use authorisation (EUA) for Sputnik V.

In September last year, Dr Reddy's partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.

The Drugs Controller General of India (DCGI) has already given the EUA nod to two COVID-19 vaccines -- Covaxin of Bharat Biotech and Covishield of Oxford-AstraZeneca, being manufactured by the Serum Institute of India in Pune.

Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of phase 3 clinical trial, which included data on 19,866 volunteers in Russia.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp